Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease

World Journal of Gastroenterology

Volumn 20, Issue 33, 2014, Pages 11505-11524

  Orel, Rok ^a   Trop, Tina Kamhi ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Gut; Inflammatory bowel disease; Microbiota; Prebiotic; Probiotic

Indexed keywords

CYTOKINE; FRUCTOSE OLIGOSACCHARIDE; INULIN; ISPAGULA; PREBIOTIC AGENT; PROBIOTIC AGENT; VSL3;

BARLEY; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); CROHN DISEASE; CYTOKINE RELEASE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HUMAN; ILEITIS; IMMUNOCOMPETENT CELL; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; INTESTINE INJURY; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REMISSION; REVIEW; SACCHAROMYCES BOULARDII; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); ULCERATIVE COLITIS; ANIMAL; COLITIS, ULCERATIVE; IMMUNOLOGY; INTESTINE; MICROBIOLOGY; MICROFLORA; TREATMENT OUTCOME;

ANIMALS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INTESTINES; MICROBIOTA; PREBIOTICS; PROBIOTICS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84909641363     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i33.11505     Document Type: Review

References (157)

1. Wehkamp J, Antoni L, Ostaff M, Stange EF. The intestinal barrier in health and chronic inflammation. Current understanding and implications for future therapeutic intervention. Germany: Falk Foundation e.V., 2013
2. Orel R. Probiotics and prebiotics in inflammatory bowel disease. In: Orel R, editor. Intestinal microbiota, probiotics and prebiotics. Comprehensive textbook for health professionals. Ljubljana, Slovenia: Institute for Probiotics and Functional Foods, ltd, 2014
3. Stephani J, Radulovic K, Niess JH. Gut microbiota, probiotics and inflammatory bowel disease. Arch Immunol Ther Exp (Warsz) 2011; 59: 161-177 [PMID: 21445715 DOI: 10.1007/s00005-011-0122-5]
4. Tsai F, Coyle WJ. The microbiome and obesity: is obesity linked to our gut flora? Curr Gastroenterol Rep 2009; 11: 307-313 [PMID: 19615307 DOI: 10.1007/s11894-009-0045-z]
5. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008; 134: 577-594 [PMID: 18242222 DOI: 10.1053/j.gastro.2007.11.059]
6. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. Diversity of the human intestinal microbial flora. Science 2005; 308: 1635-1638 [PMID: 15831718 DOI: 10.1126/science.1110591]
7. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65 [PMID: 20203603 DOI: 10.1038/nature08821]
8. Kanauchi O, Matsumoto Y, Matsumura M, Fukuoka M, Bamba T. The beneficial effects of microflora, especially obligate anaerobes, and their products on the colonic environment in inflammatory bowel disease. Curr Pharm Des 2005; 11: 1047-1053 [PMID: 15777254 DOI: 10.2174/1381612053381675]
9. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114: 262-267 [PMID: 9453485 DOI: 10.1016/s0016-5085(98)70476-7]
10. Harper PH, Lee EC, Kettlewell MG, Bennett MK, Jewell DP. Role of the faecal stream in the maintenance of Crohn's colitis. Gut 1985; 26: 279-284 [PMID: 3972275 DOI: 10.1136/gut.26.3.279]
11. de Silva HJ, Millard PR, Soper N, Kettlewell M, Mortensen N, Jewell DP. Effects of the faecal stream and stasis on the ileal pouch mucosa. Gut 1991; 32: 1166-1169 [PMID: 1955172 DOI: 10.1136/gut.32.10.1166]
12. Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, Talley NJ, Moayyedi P. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 661-673 [PMID: 21407187 DOI: 10.1038/ajg.2011.72]
13. Guslandi M. Antibiotics for inflammatory bowel disease: do they work? Eur J Gastroenterol Hepatol 2005; 17: 145-147 [PMID: 15674090 DOI: 10.1097/00042737-200502000-00003]
14. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, Rennick DM, Sartor RB. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998; 66: 5224-5231 [PMID: 9784526]
15. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernández-Sueiro JL, Balish E, Hammer RE. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180: 2359-2364 [PMID: 7964509 DOI: 10.1084/jem.180.6.2359]
16. Kishi D, Takahashi I, Kai Y, Tamagawa H, Iijima H, Obunai S, Nezu R, Ito T, Matsuda H, Kiyono H. Alteration of V beta usage and cytokine production of CD4+ TCR beta beta homodimer T cells by elimination of Bacteroides vulgatus prevents colitis in TCR alpha-chain-deficient mice. J Immunol 2000; 165: 5891-5899 [PMID: 11067950]
17. Fiorucci S, Distrutti E, Mencarelli A, Barbanti M, Palazzini E, Morelli A. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion 2002; 66: 246-256 [PMID: 12592101 DOI: 10.1159/000068362]
18. Cario E. Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 2005; 54: 1182-1193 [PMID: 15840688 DOI: 10.1136/gut.2004.062794]
19. Glasser AL, Darfeuille-Michaud A. Abnormalities in the handling of intracellular bacteria in Crohn's disease: a link between infectious etiology and host genetic susceptibility. Arch Immunol Ther Exp (Warsz) 2008; 56: 237-244 [PMID: 18726145 DOI: 10.1007/s00005-008-0026-1]
20. Girardin SE, Boneca IG, Carneiro LA, Antignac A, Jéhanno M, Viala J, Tedin K, Taha MK, Labigne A, Zähringer U, Coyle AJ, DiStefano PS, Bertin J, Sansonetti PJ, Philpott DJ. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 2003; 300: 1584-1587 [PMID: 12791997 DOI: 10.1126/science.1084677]
21. Török HP, Glas J, Tonenchi L, Mussack T, Folwaczny C. Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol 2004; 112: 85-91 [PMID: 15207785 DOI: 10.1016/j.clim.2004.03.002]
22. McGovern DP, Hysi P, Ahmad T, van Heel DA, Moffatt MF, Carey A, Cookson WO, Jewell DP. Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum Mol Genet 2005; 14: 1245-1250 [PMID: 15790594 DOI: 10.1093/hmg/ddi135]
23. Rosenstiel P, Sina C, End C, Renner M, Lyer S, Till A, Hellmig S, Nikolaus S, Fölsch UR, Helmke B, Autschbach F, Schirmacher P, Kioschis P, Hafner M, Poustka A, Mollenhauer J, Schreiber S. Regulation of DMBT1 via NOD2 and TLR4 in intestinal epithelial cells modulates bacterial recognition and invasion. J Immunol 2007; 178: 8203-8211 [PMID: 17548659]
24. Chassaing B, Darfeuille-Michaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1720-1728 [PMID: 21530738 DOI: 10.1053/j.gastro.2011.01.054]
25. Braun A, Treede I, Gotthardt D, Tietje A, Zahn A, Ruhwald R, Schoenfeld U, Welsch T, Kienle P, Erben G, Lehmann WD, Fuellekrug J, Stremmel W, Ehehalt R. Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm Bowel Dis 2009; 15: 1705-1720 [PMID: 19504612 DOI: 10.1002/ibd.20993]
26. Chiodini RJ. Crohn's disease and the mycobacterioses: a review and comparison of two disease entities. Clin Microbiol Rev 1989; 2: 90-117 [PMID: 2644025]
27. Selby W, Pavli P, Crotty B, Florin T, Radford-Smith G, Gibson P, Mitchell B, Connell W, Read R, Merrett M, Ee H, Hetzel D. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007; 132: 2313-2319 [PMID: 17570206 DOI: 10.1053/j.gastro.2007.03.031]
28. Darfeuille-Michaud A, Neut C, Barnich N, Lederman E, Di Martino P, Desreumaux P, Gambiez L, Joly B, Cortot A, Colombel JF. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998; 115: 1405-1413 [PMID: 9834268 DOI: 10.1016/s0016-5085(98)70019-8]
29. Conte MP, Schippa S, Zamboni I, Penta M, Chiarini F, Seganti L, Osborn J, Falconieri P, Borrelli O, Cucchiara S. Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut 2006; 55: 1760-1767 [PMID: 16648155 DOI: 10.1136/gut.2005.078824]
30. Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi RH, Wiedmann M, McDonough P, Kim SG, Berg D, Schukken Y, Scherl E, Simpson KW. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum. ISME J 2007; 1: 403-418 [PMID: 18043660 DOI: 10.1038/ismej.2007.52]
31. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007; 117: 514-521 [PMID: 17332878 DOI: 10.1172/JCI30587]
32. Clavel T, Haller D. Bacteria- and host-derived mechanisms to control intestinal epithelial cell homeostasis: implications for chronic inflammation. Inflamm Bowel Dis 2007; 13: 1153-1164 [PMID: 17476679 DOI: 10.1002/ibd.20174]
33. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361: 512-519 [PMID: 12583961 DOI: 10.1016/s0140-6736(03)12489-0]
34. Damaskos D, Kolios G. Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'. Br J Clin Pharmacol 2008; 65: 453-467 [PMID: 18279467 DOI: 10.1111/j.1365-2125.2008.03096.x]
35. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-434 [PMID: 17653185 DOI: 10.1038/nature06005]
36. Strober W, Murray PJ, Kitani A, Watanabe T. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 2006; 6: 9-20 [PMID: 16493424 DOI: 10.1038/nri1747]
37. Neurath MF, Fuss I, Schürmann G, Pettersson S, Arnold K, Müller-Lobeck H, Strober W, Herfarth C, Büschenfelde KH. Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease. Ann N Y Acad Sci 1998; 859: 149-159 [PMID: 9928378 DOI: 10.1111/j.1749-6632]
38. Tamboli CP, Neut C, Desreumaux P, Colombel JF. Dysbiosis in inflammatory bowel disease. Gut 2004; 53: 1-4 [PMID: 14684564 DOI: 10.1136/gut.53.1.1]
39. Sokol H, Seksik P, Rigottier-Gois L, Lay C, Lepage P, Podglajen I, Marteau P, Doré J. Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 106-111 [PMID: 16432374 DOI: 10.1097/01.mib.0000200323.38139.c6]
40. Takaishi H, Matsuki T, Nakazawa A, Takada T, Kado S, Asahara T, Kamada N, Sakuraba A, Yajima T, Higuchi H, Inoue N, Ogata H, Iwao Y, Nomoto K, Tanaka R, Hibi T. Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol 2008; 298: 463-472 [PMID: 17897884 DOI: 10.1016/j.ijmm.2007.07.016]
41. Swidsinski A, Loening-Baucke V, Vaneechoutte M, Doerffel Y. Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm Bowel Dis 2008; 14: 147-161 [PMID: 18050295 DOI: 10.1002/ibd.20330]
42. Frank DN, Robertson CE, Hamm CM, Kpadeh Z, Zhang T, Chen H, Zhu W, Sartor RB, Boedeker EC, Harpaz N, Pace NR, Li E. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 179-184 [PMID: 20839241 DOI: 10.1002/ibd.21339]
43. Walker AW, Sanderson JD, Churcher C, Parkes GC, Hudspith BN, Rayment N, Brostoff J, Parkhill J, Dougan G, Petrovska L. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol 2011; 11: 7 [PMID: 21219646 DOI: 10.1186/1471-2180-11-7]
44. Sepehri S, Kotlowski R, Bernstein CN, Krause DO. Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 675-683 [PMID: 17262808 DOI: 10.1002/ibd.20101]
45. Kleessen B, Kroesen AJ, Buhr HJ, Blaut M. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand J Gastroenterol 2002; 37: 1034-1041 [PMID: 12374228 DOI: 10.1080/003655202320378220]
46. Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P, Jian R, Doré J. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 2003; 52: 237-242 [PMID: 12524406 DOI: 10.1136/gut.52.2.237]
47. Marteau P, Pochart P, Doré J, Béra-Maillet C, Bernalier A, Corthier G. Comparative study of bacterial groups within the human cecal and fecal microbiota. Appl Environ Microbiol 2001; 67: 4939-4942 [PMID: 11571208 DOI: 10.1128/AEM.67.1 0.4939-4942.2001]
48. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122: 44-54 [PMID: 11781279 DOI: 10.1053/gast.2002.30294]
49. Barnich N, Darfeuille-Michaud A. Adherent-invasive Escherichia coli and Crohn's disease. Curr Opin Gastroenterol 2007; 23: 16-20 [PMID: 17133079 DOI: 10.1097/mog.0b013e3280105a38]
50. Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Fölsch UR, Timmis KN, Schreiber S. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004; 53: 685-693 [PMID: 15082587 DOI: 10.1136/gut.2003.025403]
51. Ott SJ, Schreiber S. Reduced microbial diversity in inflammatory bowel diseases. Gut 2006; 55: 1207 [PMID: 16849351]
52. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 2006; 55: 205-211 [PMID: 16188921 DOI: 10.1136/gut.2005.073817]
53. Dicksved J, Halfvarson J, Rosenquist M, Järnerot G, Tysk C, Apajalahti J, Engstrand L, Jansson JK. Molecular analysis of the gut microbiota of identical twins with Crohn's disease. ISME J 2008; 2: 716-727 [PMID: 18401439 DOI: 10.1038/ismej.2008.37]
54. Paul J, Verma AK, Verma R. Role of gut flora in inflammatory bowel disease-a state of art. In: Mendez-Vilas A, editor. Communicating current research and educational topics and trends in applied microbiology. Extremadura, Spain: Formatex, 2007
55. Mylonaki M, Rayment NB, Rampton DS, Hudspith BN, Brostoff J. Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 481-487 [PMID: 15867588 DOI: 10.1097/01.mib.00001569663.62651.4f]
56. Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs 2012; 72: 803-823 [PMID: 22512365 DOI: 10.2165/11632710-000000000-00000]
57. Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, Cosnes J, Corthier G, Marteau P, Doré J. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009; 15: 1183-1189 [PMID: 19235886 DOI: 10.1002/ibd.20903]
58. Martinez C, Antolin M, Santos J, Torrejon A, Casellas F, Borruel N, Guarner F, Malagelada JR. Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission. Am J Gastroenterol 2008; 103: 643-648 [PMID: 18341488 DOI: 10.1111/j.1572-0241.2007.01592.x]
59. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007; 104: 13780-13785 [PMID: 17699621 DOI: 10.1073/pnas.0706625104]
60. Gueimonde M, Ouwehand A, Huhtinen H, Salminen E, Salminen S. Qualitative and quantitative analyses of the bifidobacterial microbiota in the colonic mucosa of patients with colorectal cancer, diverticulitis and inflammatory bowel disease. World J Gastroenterol 2007; 13: 3985-3989 [PMID: 17663515]
61. Mylonaki M, Langmead L, Pantes A, Johnson F, Rampton DS. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 2004; 16: 775-778 [PMID: 15256979]
62. Vernia P, Gnaedinger A, Hauck W, Breuer RI. Organic anions and the diarrhea of inflammatory bowel disease. Dig Dis Sci 1988; 33: 1353-1358 [PMID: 3180970 DOI: 10.1007/BF01536987]
63. Thomazini CM, Samegima DA, Rodrigues MA, Victoria CR, Rodrigues J. High prevalence of aggregative adherent Escherichia coli strains in the mucosa-associated microbiota of patients with inflammatory bowel diseases. Int J Med Microbiol 2011; 301: 475-479 [PMID: 21616711 DOI: 10.1016/j.ijmm.2011.04.015]
64. Gophna U, Sommerfeld K, Gophna S, Doolittle WF, Veldhuyzen van Zanten SJ. Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis. J Clin Microbiol 2006; 44: 4136-4141 [PMID: 16988016 DOI: 10.1128/JCM.01004-06]
65. Nwosu FC, Thorkildsen LT, Avershina E, Ricanek P, Perminow G, Brackmann S, Vatn MH, Rudi K. Age-dependent fecal bacterial correlation to inflammatory bowel disease for newly diagnosed untreated children. Gastroenterol Res Pract 2013; 2013: 302398 [PMID: 23690761 DOI: 10.1155/2013/302398]
66. Florin T, Neale G, Gibson GR, Christl SU, Cummings JH. Metabolism of dietary sulphate: absorption and excretion in humans. Gut 1991; 32: 766-773 [PMID: 1855683 DOI: 10.1136/gut.32.7.766]
67. Gibson GR, Cummings JH, Macfarlane GT. Growth and activities of sulphate-reducing bacteria in gut contents of healthy subjects and patients with ulcerative colitis. FEMS Microbiol Ecol 1991; 86: 103-111 [DOI: 10.1111/j.1574-6968.1991.tb04799.x]
68. Kaakoush NO, Day AS, Huinao KD, Leach ST, Lemberg DA, Dowd SE, Mitchell HM. Microbial dysbiosis in pediatric patients with Crohn's disease. J Clin Microbiol 2012; 50: 3258-3266 [PMID: 22837318 DOI: 10.1128/JCM.01396-12]
69. Lionetti P, Callegari ML, Ferrari S, Cavicchi MC, Pozzi E, de Martino M, Morelli L. Enteral nutrition and microflora in pediatric Crohn's disease. JPEN J Parenter Enteral Nutr 2005; 29: S173-S175; discussion S175-178, S184-188 [PMID: 15980280 DOI: 10.1177/01486071050290S4S173]
70. Gosiewski T, Strus M, Fyderek K, Kowalska-Duplaga K, Wedrychowicz A, Jedynak-Wasowicz U, Sladek M, Pieczarkowski S, Adamski P, Heczko PB. Horizontal distribution of the fecal microbiota in adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2012; 54: 20-27 [PMID: 21788912 DOI: 10.1097/MPG.0b013e31822d53e5]
71. Fyderek K, Strus M, Kowalska-Duplaga K, Gosiewski T, Wedrychowicz A, Jedynak-Wasowicz U, Sładek M, Pieczarkowski S, Adamski P, Kochan P, Heczko PB. Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease. World J Gastroenterol 2009; 15: 5287-5294 [PMID: 19908336 DOI: 10.3748/wjg.15.5287]
72. Kellermayer R, Mir SA, Nagy-Szakal D, Cox SB, Dowd SE, Kaplan JL, Sun Y, Reddy S, Bronsky J, Winter HS. Microbiota separation and C-reactive protein elevation in treatment-naïve pediatric granulomatous Crohn disease. J Pediatr Gastroenterol Nutr 2012; 55: 243-250 [PMID: 22699834 DOI: 10.1097/MPG.0b013e3182617c16]
73. Hansen R, Reiff C, Russell RK, Bisset WM, Berry SH, Mukhopadhya I, Thomson JM, El-Omar EM, Hold GL. Colonic mucosal bacterial diversity of de-novo extensive paediatric ulcerative colitis by next-generation sequencing. Gut 2011; 60: A146-A147 [DOI: 10.1136/gut.2011.239301.310]
74. Hansen R, Russell RK, Reiff C, Louis P, McIntosh F, Berry SH, Mukhopadhya I, Bisset WM, Barclay AR, Bishop J, Flynn DM, McGrogan P, Loganathan S, Mahdi G, Flint HJ, El-Omar EM, Hold GL. Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis. Am J Gastroenterol 2012; 107: 1913-1922 [PMID: 23044767 DOI: 10.1038/ajg.2012.335]
75. Hansen R, Berry SH, Mukhopadhya I, Thomson JM, Saunders KA, Nicholl CE, Bisset WM, Loganathan S, Mahdi G, Kastner-Cole D, Barclay AR, Bishop J, Flynn DM, McGrogan P, Russell RK, El-Omar EM, Hold GL. The microaerophilic microbiota of de-novo paediatric inflammatory bowel disease: the BISCUIT study. PLoS One 2013; 8: e58825 [PMID: 23554935 DOI: 10.1371/journal.pone.0058825]
76. Mack DR. Probiotics in inflammatory bowel diseases and associated conditions. Nutrients 2011; 3: 245-264 [PMID: 22254095 DOI: 10.3390/nu3020245]
77. Food and Agriculture Organisation of the United Nations; World Health Organisation. Guidelines for the evaluation of probiotics in food: joint FAO/WHO Working Group report on drafting guidelines for the evaluation of probiotics in food. Available from: URL: ftp://ftp.fao.org/es/esn/food/wgreport2.pdf
78. Borchers AT, Selmi C, Meyers FJ, Keen CL, Gershwin ME. Probiotics and immunity. J Gastroenterol 2009; 44: 26-46 [PMID: 19159071 DOI: 10.1007/s00535-008-2296-0]
79. Whelan K, Myers CE. Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials. Am J Clin Nutr 2010; 91: 687-703 [PMID: 20089732 DOI: 10.3945/ajcn.2009.28759]
80. Liong MT. Safety of probiotics: translocation and infection. Nutr Rev 2008; 66: 192-202 [PMID: 18366533 DOI: 10.1111/j.1753-4887.2008.00024.x]
81. Thomas DW, Greer FR. Probiotics and prebiotics in pediatrics. Pediatrics 2010; 126: 1217-1231 [PMID: 21115585 DOI: 10.1542/peds.2010-2548]
82. Quigley EM. Prebiotics and probiotics: their role in the management of gastrointestinal disorders in adults. Nutr Clin Pract 2012; 27: 195-200 [PMID: 22127952 DOI: 10.1177/0884533611423926]
83. Kotzampassi K, Giamarellos-Bourboulis EJ. Probiotics for infectious diseases: more drugs, less dietary supplementation. Int J Antimicrob Agents 2012; 40: 288-296 [PMID: 22858373 DOI: 10.1016/j.ijantimicag.2012.06.006]
84. Collado MC, Meriluoto J, Salminen S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Lett Appl Microbiol 2007; 45: 454-460 [PMID: 17897389 DOI: 10.1111/j.1472-765X.2007.02212.x]
85. Veerappan GR, Betteridge J, Young PE. Probiotics for the treatment of inflammatory bowel disease. Curr Gastroenterol Rep 2012; 14: 324-333 [PMID: 22581276 DOI: 10.1007/s11894-012-0265-5]
86. Garcia Vilela E, De Lourdes De Abreu Ferrari M, Oswaldo Da Gama Torres H, Guerra Pinto A, Carolina Carneiro Aguirre A, Paiva Martins F, Marcos Andrade Goulart E, Sales Da Cunha A. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand J Gastroenterol 2008; 43: 842-848 [PMID: 18584523 DOI: 10.1080/00365520801943354]
87. Mack DR, Ahrne S, Hyde L, Wei S, Hollingsworth MA. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut 2003; 52: 827-833 [PMID: 12740338 DOI: 10.1136/gut.52.6.827]
88. Caballero-Franco C, Keller K, De Simone C, Chadee K. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 2007; 292: G315-G322 [PMID: 16973917 DOI: 10.1152/ajpgi.00265.2006]
89. Karczewski J, Troost FJ, Konings I, Dekker J, Kleerebezem M, Brummer RJ, Wells JM. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. Am J Physiol Gastrointest Liver Physiol 2010; 298: G851-G859 [PMID: 20224007 DOI: 10.1152/ajpgi.00327.2009]
90. Ukena SN, Singh A, Dringenberg U, Engelhardt R, Seidler U, Hansen W, Bleich A, Bruder D, Franzke A, Rogler G, Suerbaum S, Buer J, Gunzer F, Westendorf AM. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One 2007; 2: e1308 [PMID: 18074031 DOI: 10.1371/journal.pone.0001308]
91. Macho Fernandez E, Pot B, Grangette C. Beneficial effect of probiotics in IBD: are peptidogycan and NOD2 the molecular key effectors? Gut Microbes 2011; 2: 280-286 [PMID: 22067939 DOI: 10.4161/gmic.2.5.18255]
92. Prisciandaro L, Geier M, Butler R, Cummins A, Howarth G. Probiotics and their derivatives as treatments for inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 1906-1914 [PMID: 19373788 DOI: 10.1002/ibd.20938]
93. O'Mahony C, Scully P, O'Mahony D, Murphy S, O'Brien F, Lyons A, Sherlock G, MacSharry J, Kiely B, Shanahan F, O' Mahony L. Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog 2008; 4: e1000112 [PMID: 18670628 DOI: 10.1371/journal.ppat.1000112]
94. Matsumoto S, Watanabe N, Imaoka A, Okabe Y. Preventive effects of Bifidobacterium- and Lactobacillus-fermented milk on the development of inflammatory bowel disease in senescence-accelerated mouse P1/Yit strain mice. Digestion 2001; 64: 92-99 [PMID: 11684822 DOI: 10.1159/000048846]
95. Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet 1989; 1: 164 [PMID: 2563083 DOI: 10.1016/s0140-6736(89)91183-5]
96. Borody TJ, Warren EF, Leis S, Surace R, Ashman O. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003; 37: 42-47 [PMID: 12811208 DOI: 10.1097/00004836-200307000-00012]
97. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 2004; 10: PI126-PI131 [PMID: 15507864]
98. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, Sartor RB. VSL#3 probi-otic- mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005; 100: 1539-1546 [PMID: 15984978]
99. Huynh HQ, deBruyn J, Guan L, Diaz H, Li M, Girgis S, Turner J, Fedorak R, Madsen K. Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. Inflamm Bowel Dis 2009; 15: 760-768 [PMID: 19067432 DOI: 10.1002/ibd.20816]
100. Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, Forti G, Morini S, Hassan C, Pistoia MA, Modeo ME, Rodino' S, D'Amico T, Sebkova L, Sacca' N, Di Giulio E, Luzza F, Imeneo M, Larussa T, Di Rosa S, Annese V, Danese S, Gasbarrini A. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010; 105: 2218-2227 [PMID: 20517305 DOI: 10.1038/ajg.2010.218]
101. Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P, Tandon RK. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 1202-1209, 1209.e1 [PMID: 19631292 DOI: 10.1016/j.cgh.2009.07.016]
102. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009; 104: 437-443 [PMID: 19174792 DOI: 10.1038/ajg.2008.118]
103. Tsuda Y, Yoshimatsu Y, Aoki H, Nakamura K, Irie M, Fukuda K, Hosoe N, Takada N, Shirai K, Suzuki Y. Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy. Scand J Gastroenterol 2007; 42: 1306-1311 [PMID: 17852859 DOI: 10.1080/00365520701396091]
104. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 635-639 [PMID: 10466665 DOI: 10.1016/s0140-6737(98)06343-0]
105. Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A, Otsuka M, Hasunuma O, Kurihara R, Iwasaki A, Arakawa Y. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004; 20: 1133-1141 [PMID: 15569116 DOI: 10.1111/j.1365-2036.2004.02268.x]
106. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifido-bacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003; 22: 56-63 [PMID: 12569115 DOI: 10.1080/07315724.2003.10719276]
107. Oliva S, Di Nardo G, Ferrari F, Mallardo S, Rossi P, Patrizi G, Cucchiara S, Stronati L. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther 2012; 35: 327-334 [PMID: 22150569 DOI: 10.1111/j.1365-2036.2011.04939.x]
108. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15: 697-698 [PMID: 12840682 DOI: 10.1097/00042737-200306000-00017]
109. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'neil DA, Macfarlane GT. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005; 54: 242-249 [PMID: 15647189 DOI: 10.1136/gut.2004.044834]
110. Ishikawa H, Matsumoto S, Ohashi Y, Imaoka A, Setoyama H, Umesaki Y, Tanaka R, Otani T. Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study. Digestion 2011; 84: 128-133 [PMID: 21525768 DOI: 10.1159/000322977]
111. Mallon P, McKay D, Kirk S, Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; (4): CD005573 [PMID: 17943867 DOI: 10.1002/14651858.CD005573.pub2]
112. Naidoo K, Gordon M, Fagbemi AO, Thomas AG, Akobeng AK. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2011; (12): CD007443 [PMID: 22161412]
113. Zigra PI, Maipa VE, Alamanos YP. Probiotics and remission of ulcerative colitis: a systematic review. Neth J Med 2007; 65: 411-418 [PMID: 18079563]
114. Floch MH, Walker WA, Madsen K, Sanders ME, Macfarlane GT, Flint HJ, Dieleman LA, Ringel Y, Guandalini S, Kelly CP, Brandt LJ. Recommendations for probiotic use-2011 update. J Clin Gastroenterol 2011; 45 Suppl: S168-S171 [PMID: 21992958 DOI: 10.1097/MCG.0b013e318230928b]
115. Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853-858 [PMID: 9354192 DOI: 10.1046/j.1365-2036.1997.00225.x]
116. Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623 [PMID: 15479682 DOI: 10.1136/gut.2003.037747]
117. Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Rigante D, Cazzato IA, Ojetti V, Armuzzi A, Gasbarrini G, Gasbarrini A. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 1567-1574 [PMID: 16696804 DOI: 10.1111/j.1365-2036.2006.02927.x]
118. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, Matteuzzi D, Campieri M. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1103-1108 [PMID: 10468688 DOI: 10.1046/j.1365-2036.1999.00560.x]
119. Cui HH, Chen CL, Wang JD, Yang YJ, Cun Y, Wu JB, Liu YH, Dan HL, Jian YT, Chen XQ. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol 2004; 10: 1521-1525 [PMID: 15133865]
120. Shanahan F, Guarner F, Von Wright A, Vilpponen-Salmela T, O'Donoghue D, Kiely B. A one year, double-blind, placebo-controlled trial of a Lactobacillus or a Bifidobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology 2006; 130 Suppl 2: A-44
121. Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. A double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subspecies lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis 2011; 5: 115-121 [DOI: 10.1016/j.crohns.2010.11.004]
122. Schmoldt A, Benthe HF, Haberland G. Digitoxin metabolism by rat liver microsomes. Biochem Pharmacol 1975; 24: 1639-1641 [PMID: 10 DOI: 10.1002/14651858.CD007443.pub2]
123. Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003; 17: 509-515 [PMID: 12622759 DOI: 10.1046/j.1365-2036.2003.01465.x]
124. Laake KO, Bjørneklett A, Aamodt G, Aabakken L, Jacobsen M, Bakka A, Vatn MH. Outcome of four weeks' intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis. Scand J Gastroenterol 2005; 40: 43-51 [PMID: 15841713 DOI: 10.1080/00365520410009339]
125. Gionchetti P, Rizzello F, Morselli C, Poggioli G, Tambasco R, Calabrese C, Brigidi P, Vitali B, Straforini G, Campieri M. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 2007; 50: 2075-2082; discussion 2082-2084 [PMID: 17934776 DOI: 10.1007/s10350-007-9068-4]
126. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 305-309 [PMID: 10930365 DOI: 10.1053/gast.2000.9370]
127. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124: 1202-1209 [PMID: 12730861 DOI: 10.1016/s0016-5085(03)00171-9]
128. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53: 108-114 [PMID: 14684584 DOI: 10.1136/gut.53.1.108]
129. Pronio A, Montesani C, Butteroni C, Vecchione S, Mumolo G, Vestri A, Vitolo D, Boirivant M. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis 2008; 14: 662-668 [PMID: 18240282 DOI: 10.1002/ibd.20369]
130. Shen B, Brzezinski A, Fazio VW, Remzi FH, Achkar JP, Bennett AE, Sherman K, Lashner BA. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther 2005; 22: 721-728 [PMID: 16197493 DOI: 10.1111/j.1365-2036.2005.02642.x]
131. Gosselink MP, Schouten WR, van Lieshout LM, Hop WC, Laman JD, Ruseler-van Embden JG. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004; 47: 876-884 [PMID: 15108026 DOI: 10.1007/s10350-004-0525-z]
132. Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 2010; (6): CD001176 [PMID: 20556748 DOI: 10.1002/14651858.CD001176.pub2]
133. Pardi DS, D'Haens G, Shen B, Campbell S, Gionchetti P. Clinical guidelines for the management of pouchitis. Inflamm Bowel Dis 2009; 15: 1424-1431 [PMID: 19685489 DOI: 10.1002/ibd.21039]
134. Gupta P, Andrew H, Kirschner BS, Guandalini S. Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000; 31: 453-457 [PMID: 11045848 DOI: 10.1097/00005176-200010000-00024]
135. Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 2004; 4: 5 [PMID: 15113451 DOI: 10.1186/1471-230X-4-5]
136. Butterworth AD, Thomas AG, Akobeng AK. Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008; (3): CD006634 [PMID: 18646162 DOI: 10.1002/14651858.CD006634.pub2]
137. Fujimori S, Tatsuguchi A, Gudis K, Kishida T, Mitsui K, Ehara A, Kobayashi T, Sekita Y, Seo T, Sakamoto C. High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. J Gastroenterol Hepatol 2007; 22: 1199-1204 [PMID: 17688660 DOI: 10.1111/j.1440-1746.2006.04535.x]
138. Steed H, Macfarlane GT, Blackett KL, Bahrami B, Reynolds N, Walsh SV, Cummings JH, Macfarlane S. Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease. Aliment Pharmacol Ther 2010; 32: 872-883 [PMID: 20735782 DOI: 10.1111/j.1365-2036.2010.04417.x]
139. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000; 45: 1462-1464 [PMID: 10961730 DOI: 10.1016/s1590-8658(00)80218-2]
140. Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, Goldin B, Hartigan L, Kugathasan S, Levy J, Murray KF, Oliva-Hemker M, Rosh JR, Tolia V, Zholudev A, Vanderhoof JA, Hibberd PL. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005; 11: 833-839 [PMID: 16116318 DOI: 10.1097/01.mib.0000175905.00212.2c]
141. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002; 51: 405-409 [PMID: 12171964 DOI: 10.1136/gut.51.3.405]
142. Marteau P, Lémann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, Cadiot G, Soulé JC, Bourreille A, Metman E, Lerebours E, Carbonnel F, Dupas JL, Veyrac M, Coffin B, Moreau J, Abitbol V, Blum-Sperisen S, Mary JY. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 2006; 55: 842-847 [PMID: 16377775 DOI: 10.1136/gut.2005.076604]
143. Van Gossum A, Dewit O, Louis E, de Hertogh G, Baert F, Fontaine F, DeVos M, Enslen M, Paintin M, Franchimont D. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm Bowel Dis 2007; 13: 135-142 [PMID: 17206696 DOI: 10.1002/ibd.20063]
144. Chermesh I, Tamir A, Reshef R, Chowers Y, Suissa A, Katz D, Gelber M, Halpern Z, Bengmark S, Eliakim R. Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn's disease. Dig Dis Sci 2007; 52: 385-389 [PMID: 17211699 DOI: 10.1007/s10620-006-9549-7]
145. Madsen K, Backer JL, Leddin D, Dieleman LA, Bitton A, Feagan B, Petrunia DM, Chiba N, Enns RA, Fedorak R. A randomized trial of VSL#3 for the prevention of endoscopic recurrence following surgery for Crohn's disease. Gastroenterology 2008; 134 (Suppl 1): A361 [DOI: 10.1016/s0016-5085(08)61682-0]
146. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2006; (4): CD004826 [PMID: 17054217 DOI: 10.1002/14651858.CD004826]
147. Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC. Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev 2009; (4): CD006873 [PMID: 19821389 DOI: 10.1002/14651858.CD006873.pub2]
148. Rahimi R, Nikfar S, Rahimi F, Elahi B, Derakhshani S, Vafaie M, Abdollahi M. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 2008; 53: 2524-2531 [PMID: 18270836 DOI: 10.1007/s10620-007-0171-0]
149. Shen J, Ran HZ, Yin MH, Zhou TX, Xiao DS. Meta-analysis: the effect and adverse events of Lactobacilli versus placebo in maintenance therapy for Crohn disease. Intern Med J 2009; 39: 103-109 [PMID: 19220543 DOI: 10.1111/j.1445-5994.2008.01791.x]
150. Hallert C, Kaldma M, Petersson BG. Ispaghula husk may relieve gastrointestinal symptoms in ulcerative colitis in remission. Scand J Gastroenterol 1991; 26: 747-750 [PMID: 1654592 DOI: 10.3109/00365529108998594]
151. Fernández-Bañares F, Hinojosa J, Sánchez-Lombraña JL, Navarro E, Martínez-Salmerón JF, García-Pugés A, González-Huix F, Riera J, González-Lara V, Domínguez-Abascal F, Giné JJ, Moles J, Gomollón F, Gassull MA. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 1999; 94: 427-433 [PMID: 10022641]
152. Casellas F, Borruel N, Torrejón A, Varela E, Antolin M, Guarner F, Malagelada JR. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. Aliment Pharmacol Ther 2007; 25: 1061-1067 [PMID: 17439507 DOI: 10.1111/j.1365-2036.2007.03288.x]
153. Hafer A, Krämer S, Duncker S, Krüger M, Manns MP, Bischoff SC. Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study. BMC Gastroenterol 2007; 7: 36 [PMID: 17784949 DOI: 10.1186/1471-230X-7-36]
154. Kanauchi O, Mitsuyama K, Homma T, Takahama K, Fujiyama Y, Andoh A, Araki Y, Suga T, Hibi T, Naganuma M, Asakura H, Nakano H, Shimoyama T, Hida N, Haruma K, Koga H, Sata M, Tomiyasu N, Toyonaga A, Fukuda M, Kojima A, Bamba T. Treatment of ulcerative colitis patients by long-term administration of germinated barley foodstuff: multi-center open trial. Int J Mol Med 2003; 12: 701-704 [PMID: 14532996]
155. Hanai H, Kanauchi O, Mitsuyama K, Andoh A, Takeuchi K, Takayuki I, Araki Y, Fujiyama Y, Toyonaga A, Sata M, Kojima A, Fukuda M, Bamba T. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med 2004; 13: 643-647 [PMID: 15067363]
156. Lindsay JO, Whelan K, Stagg AJ, Gobin P, Al-Hassi HO, Rayment N, Kamm MA, Knight SC, Forbes A. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut 2006; 55: 348-355 [PMID: 16162680 DOI: 10.1136/gut.2005.074971]
157. Benjamin JL, Hedin CR, Koutsoumpas A, Ng SC, McCarthy NE, Hart AL, Kamm MA, Sanderson JD, Knight SC, Forbes A, Stagg AJ, Whelan K, Lindsay JO. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut 2011; 60: 923-929 [PMID: 21262918 DOI: 10.1136/gut.2010.232025]